Roflumilast (trade names Daxas Daliresp) is a drug which acts as a selective long-acting inhibitor of the enzyme PDE-4. It has anti-inflammatory effects and is under development as an orally administered drug for the treatment of inflammatory conditions of the lungs such as asthma and chronic obstructive pulmonary disease (COPD).In June 2010 Daxas was approved in the EU for severe COPD associated with chronic bronchitis.
This page contains content from the copyrighted Wikipedia article "Roflumilast"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
